Skip to main content

Product Substitution For Excedrin Announced

  • No image available
Recall Date:
June 07, 1977

Recall Details



June 7, 1977


Release # 77-059

WASHINGTON, D.C. (June 7) -- Bristol Myers Products, a division of Bristol Myers Company, and the Consumer Product Safety Commission (CPSC) announced today a product substitution of the company's 225 tablet package size and 375 tablet size of Excedrin analgesic tablets which were distributed nationwide prior to April 1977. CPSC testing found same packages for this product failed to comply with Federal regulations requiring that the packages be child-resistant.

The product substitution covers warehouse inventories of those major wholesale and retail customers handling approximately 81% of the merchandise. Existing inventories of these packages are being retrieved and replaced by upgraded packages which were tested by Bristol Myers to assure CPSC compliance. The product substitution will involve approximately 150,000 packages and will be completed by the middle of June. These two sizes represent less than 3% of Excedrin analgesic annual unit sales volume.

Bristol Myers Products, in addition, has improved its packages for these sizes of Excedrin analgesic products and has expanded its quality control program to reduce the likelihood of similar situations arising in the future.

This program is not a substitute for any legal action which may be deemed necessary by CPSC.

Choose Your Recall Emails Get Notified About Each Recall via Email.
About the U.S. CPSC
The U.S. Consumer Product Safety Commission (CPSC) is charged with protecting the public from unreasonable risks of injury or death associated with the use of thousands of types of consumer products. Deaths, injuries, and property damage from consumer product incidents cost the nation more than $1 trillion annually. CPSC’s work to ensure the safety of consumer products has contributed to a decline in the rate of deaths and injuries associated with consumer products over the past 40 years. Federal law bars any person from selling products subject to a publicly announced voluntary recall by a manufacturer or a mandatory recall ordered by the Commission.
For lifesaving information: